Stada Arzneimittel’s (OTCMKTS:STDAF) “Sell” Rating Reiterated at Nord/LB

Nord/LB restated their sell rating on shares of Stada Arzneimittel (OTCMKTS:STDAF) in a research report released on Tuesday, January 2nd.

Separately, DZ Bank reiterated a sell rating on shares of Stada Arzneimittel in a report on Monday, January 1st.

Stada Arzneimittel (OTCMKTS:STDAF) opened at $107.88 on Tuesday. The firm has a market capitalization of $6,725.14, a P/E ratio of 65.78 and a beta of -1.76. Stada Arzneimittel has a twelve month low of $51.40 and a twelve month high of $100.50.

TRADEMARK VIOLATION WARNING: This piece was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at

Stada Arzneimittel Company Profile

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications.

Receive News & Ratings for Stada Arzneimittel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stada Arzneimittel and related companies with's FREE daily email newsletter.

Leave a Reply